1 active not recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Solid Neoplasms: new trials by email Literature Review of Solid Neoplasms trials Research Report on Solid Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Dazostinag, Pembrolizumab, Platinum - Solid Neoplasms | Phase 1 / Phase 2 | Completed | Takeda | 248 | 2020-07-22 | 2026-10-22 |
| A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor E7389-LF, Nivolumab - Solid Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Eisai Co., Ltd. | 125 | 2019-09-05 | 2026-10-13 |
Neoplasms (1)
Fluorouracil (1) · Nivolumab (1) · Platinum (1) · pembrolizumab (1)
Eisai Co., Ltd. (1) · Takeda (1)
Japan (2) · Austria (1) · Canada (1) · China (1) · France (1) · Israel (1) · Poland (1) · Puerto Rico (1) · Switzerland (1) · United Kingdom (1) · United States (1)
PMID 36923556, PMID 38295160, PMID 39516370, PMID 41888610
2023 (1)